Cardiovascular and metabolic diseases including obesity remain important areas of unmet medical need, and we plan to continue applying our global capabilities to advance a pipeline of investigational treatments that have the potential to fill critical gaps in patient care, including continued development of our oral GIPR antagonist candidate and other earlier obesity programs, said Chris Boshoff, MD, PhD, Chief Scientific Officer and President, Research and Development at Pfizer
The FDA approved Zepbound for chronic weight management in adults with obesity, indicated for adults with a BMI of 30 or higher and those with a BMI of 27 or more with metabolic conditions such as type 2 diabetes, hypertension, cardiovascular disease or sleep apnea
While this effect is uncommon , our experience at Revolution Health & Wellness shows that a small number of patients experience either a reduction or occasionally even an increase in sexual desire while on GLP-1 medications
non-osteoporosis) were compared using independent t-tests for continuous variables and chi-square tests for categorical variables
Recent studies are identifying plant extracts as potential GLP-1 secretagogues